Raymond James Financial
RLMD icon

Raymond James Financial’s Relmada Therapeutics RLMD Stock Holding History

Raymond James Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-587
Closed -$352 – 6386
2025
Q2 		$352 Buy
+587
New +$301 ﹤0.01% 6715

Other funds holding RLMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Raymond James Financial's RLMD Position: Q3 2025 in Review

Raymond James Financial sold out of Relmada Therapeutics (RLMD) in Q3 2025, closing a stake of 587 shares — an estimated $352 sold.

Raymond James Financial first reported a position in RLMD in Q2 2025 and held it in 1 quarter. The position peaked at $352 in Q2 2025. 44 funds tracked by Wall St. Rank hold RLMD as of Q3 2025.

  • Raymond James Financial reported no remaining Relmada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 587 Relmada Therapeutics shares in Q3 2025, an estimated $352.
  • Raymond James Financial first reported a position in Relmada Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Relmada Therapeutics position peaked at $352 in Q2 2025.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.